Evidence map›Paper›PMID 35235772›Full record

ArticleCell metabolism2022

SARS-CoV-2 pirates the kidneys: A scar(y) story.

Jochen Reiser, Ryan Spear, Shengyuan Luo

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jochen ReiserDepartment of Internal Medicine, Rush University, Chicago, IL 60612, USA. Electronic address: jochen_reiser@rush.edu.
Ryan SpearDepartment of Internal Medicine, Rush University, Chicago, IL 60612, USA.
Shengyuan LuoDepartment of Internal Medicine, Rush University, Chicago, IL 60612, USA.
Rush University · US

Funding

The KIDCOV Study: Assessment of Kidney Injury and Associated Risk Factors for SARS-CoV-2R01DK109720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REISER, JOCHEN, SARWAL, MINNIE M · 2017 to 2021
$3.2M
suPAR and renal fibrosisR01DK125858 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEI, DAVID CHANGLI · 2020 to 2024
$2.2M
suPAR and APOL1-CKD in Sub-Saharan AfricaR01DK113761 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI PAREKH, RULAN S, REISER, JOCHEN · 2018 to 2020
$890k
NIDDK NIH HHS R01 DK109720NIDDK NIH HHS R01 DK113761NIDDK NIH HHS R01 DK125858
6 · The paper itself

Abstract

SARS-CoV-2 can cause diverse severe and lasting damage to the kidneys. In the latest issue of Cell Stem Cell, Jansen et al. utilized data gleaned from human kidney autopsies and human induced pluripotent stem cell-derived kidney organoids to investigate the direct effects of SARS-CoV-2 infection on kidney cells. They found that such infections resulted in renal scarring (notably, tubulointerstitial fibrosis).

Indexed as

COVID-19Induced Pluripotent Stem CellsCicatrixHumansKidneySARS-CoV-2

Identifiers

PMID35235772
PMCPMC8886684
OpenAlexW4214493177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.